SCHEMBL493675

SCHEMBL493675

COc1ccccc1-c1noc(C(=O)O)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.64
TP53 P04637 6/20 0.64
RAB9A P51151 6/20 0.64
SMN1; SMN2 Q16637 6/20 0.64
NPC1 O15118 6/20 0.64
L3MBTL1 Q9Y468 2/20 0.64
TSHR P16473 6/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
HTT P42858 1/20 0.55
HSD17B10 Q99714 4/20 0.55
KDM4E B2RXH2 4/20 0.55
HPGD P15428 3/20 0.55
NPSR1 Q6W5P4 2/20 0.55
POLB P06746 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
S1PR1 P21453 2/20 0.50
GAA P10253 1/20 0.50
ALOX15 P16050 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL493192 0.82 NPC1 (0.56) ALDH1A1TP53RAB9ASMN1; SMN2NPC1
SCHEMBL3667161 0.81 ALDH1A1 (0.59) ALDH1A1TP53RAB9ASMN1; SMN2NPC1
SCHEMBL5606882 0.79 MAPT (0.43) ALDH1A1TP53RAB9ASMN1; SMN2NPC1
SCHEMBL6328368 0.78 ALDH1A1 (0.67) ALDH1A1TP53RAB9ASMN1; SMN2NPC1
SCHEMBL5606878 0.78 NPC1 (0.41) ALDH1A1TP53RAB9ASMN1; SMN2NPC1
SCHEMBL1250902 0.78 SMN1; SMN2 (0.67) ALDH1A1TP53RAB9ASMN1; SMN2NPC1
SCHEMBL385137 0.77 ALDH1A1 (0.63) ALDH1A1TP53RAB9ASMN1; SMN2NPC1
SCHEMBL12171135 0.76 SMN1; SMN2 (0.70) ALDH1A1TP53RAB9ASMN1; SMN2NPC1
SCHEMBL20405482 0.76 SMN1; SMN2 (0.53) ALDH1A1TP53RAB9ASMN1; SMN2NPC1
SCHEMBL5607655 0.76 TTR (0.46) ALDH1A1TP53RAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139851-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-01-06 EP claimed
US-20080306084-A1 Substituted Amide Compounds GRUENENTHAL GMBH (DE) 2008-12-11 US claimed
WO-2008131946-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO claimed
US-8106055-B2 Substituted amide compounds GRUENENTHAL GMBH (DE) 2012-01-31 US disclosed
EP-2139851-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-01-06 EP disclosed
US-20080306084-A1 Substituted Amide Compounds GRUENENTHAL GMBH (DE) 2008-12-11 US disclosed
WO-2008131946-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306084-A1 Substituted Amide Compounds OPRK1, NAA50, ACMSD ALDH1A1 1349/4885TP53 4136/4885RAB9A 2004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.